Table 1.

Screening scenarios considered in the evaluation

Screening and triage technology	Screening age, frequency and number of lifetime screening events
Primary VIAa	• 3 yearly, 25–50 years (9×)
Cytology, HPV triage for ASC-USb
Primary HPVa	• 3 yearly, 25–50 years (9×) • 5 yearly, 25–50 years (6×) • 10 yearly, 25–50 years (3×) • 10 yearly, 30–50 years (3×) • 10 yearly, 35–45 years (2×) ‘WHO elimination strategy’5
HPV, HPV 16/18 triagec
HPV, VIA triaged
HPV, colposcopy triage
HPV, cytology triageb

^aAll HPV⁺ women treated after assessment of eligibility for ablative treatment for same-day ablation. ^bHPV⁺ women or women with cytology > ASC-US referred to colposcopy. ^cHPV 16/18-positive women treated after assessment of eligibility for ablative treatment and women positive for only other high-risk HPV types are treated only if VIA triage positive. ^dVIA triage-positive women treated after assessment of eligibility for ablative treatment. The ‘WHO elimination strategy’ refers to the screening test, ages and frequencies assumed in the earlier analysis of the cervical cancer elimination timeline^2,6.